Polyethylene coated liposomal formulation of doxirubicin.
Avoid uptake by the reticuloendothelial system and remains in the circulation longer than doxirubicin allowing greater distribution in tumors where vessels are abnormally permeable.
Associated with less risk for neutropenia, anemia, alopecia and cardiotoxicity than doxirubicin alone.
Associated with more palmar-plantar dysesthesia than doxorubicin.
Similar response rate to soft tissue sarcomas as with doxorubicin.